Novartis India Ltd vs Procter Gamble Health Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 07, 2026

Key Highlights

The Latest Trading Price of Novartis India Ltd is ₹ 1065 as of 07 May 15:30 . The p/e ratio of Novartis India Ltd changed from 19.2 to 29.8 over 5 quarters. This represents a CAGR of 42.15% The p/e ratio of Procter & Gamble Health Ltd changed from 52.5 to 0 over 9 quarters. This represents a CAGR of -100.00% The market cap of Novartis India Ltd changed from ₹ 1938 crore to ₹ 2539 crore over 5 quarters. This represents a CAGR of 24.13% The market cap of Procter & Gamble Health Ltd changed from ₹ 9285 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of -100.00% The revenue of Novartis India Ltd for the Dec '25 is ₹ 94.65 crore as compare to the Sep '25 revenue of ₹ 99.73 crore. This represent the decline of -5.09% The revenue of Procter & Gamble Health Ltd for the Dec '25 is ₹ 378.22 crore as compare to the Sep '25 revenue of ₹ 329.87 crore. This represent the growth of 14.66% The ebitda of Novartis India Ltd for the Dec '25 is ₹ 31.11 crore as compare to the Sep '25 ebitda of ₹ 33.28 crore. This represent the decline of -6.52% The ebitda of Procter & Gamble Health Ltd for the Dec '25 is ₹ 114.82 crore as compare to the Sep '25 ebitda of ₹ 125.22 crore. This represent the decline of -8.31% The net profit of Novartis India Ltd changed from ₹ 25.45 crore to ₹ 16.09 crore over 7 quarters. This represents a CAGR of -23.05% The net profit of Procter & Gamble Health Ltd changed from ₹ 46.56 crore to ₹ 77.59 crore over 7 quarters. This represents a CAGR of 33.89% The dividend payout of Novartis India Ltd changed from 61.15 % to 72.43 % over 5 quarters. This represents a CAGR of 14.50% The dividend payout of Procter & Gamble Health Ltd changed from 122.06 % to 0 % over 9 quarters. This represents a CAGR of -100.00% .

About Novartis India Ltd

Novartis India Limited (NIL) is a subsidiary of Swiss giant Novartis, the world's second largest pharmaceutical company was incorporated on 13 December 1947.
The Company is engaged in manufacturing and marketing of drugs, pharmaceutical products and formulations for consumer healthcare and animal healthcare; it operates into four segments such as Pharmaceuticals, Generics, Over the Trade Counter and Animal Health. The origin of Novartis is linked to the origin of three distinct companies namely Geigy, Ciba, and Sandoz.
The history of Geigy goes back to the middle of the 18th century, Ciba was founded around 1860, and Sandoz was set-up in 1886.
In 1970 Ciba and Geigy merged to form Ciba-Geigy Ltd. Sandoz and Ciba-Geigy Ltd continued as separate entities for the next 25 years.
In 1996, in one of the largest corporate mergers in history Sandoz and Ciba-Geigy Ltd.

About Procter & Gamble Health Ltd

Procter & Gamble Health Limited was erstwhile incorporated as E Merck (India) Limited in 1967.
The Company's name was changed from E Merck (India) Limited to Merck Limited on March 27, 2002.
Later, the name of the Company was changed to Procter & Gamble Health Limited on 6 May, 2019.
The company was set up to take over the business of the Indian branch of Emeda Exports with all their assets and liabilities.
The company is a 51% subsidiary of German firm Merck KGaA, is a leading player in vitamin formulations. Procter & Gamble Health Limited is an Indian-based company principally engaged in the business of manufacturing and marketing of pharmaceuticals and chemicals.

FAQs for the comparison of Novartis India Ltd and Procter & Gamble Health Ltd

Which company has a larger market capitalization, Novartis India Ltd or Procter & Gamble Health Ltd?

Market cap of Novartis India Ltd is 2,630 Cr while Market cap of Procter & Gamble Health Ltd is 8,821 Cr

What are the key factors driving the stock performance of Novartis India Ltd and Procter & Gamble Health Ltd?

The stock performance of Novartis India Ltd and Procter & Gamble Health Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Novartis India Ltd and Procter & Gamble Health Ltd?

As of May 7, 2026, the Novartis India Ltd stock price is INR ₹1065.45. On the other hand, Procter & Gamble Health Ltd stock price is INR ₹5314.25.

How do dividend payouts of Novartis India Ltd and Procter & Gamble Health Ltd compare?

To compare the dividend payouts of Novartis India Ltd and Procter & Gamble Health Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.